- Belgian neurotech startup ReVision Implant has raised €4M in an oversubscribed round from private investors, clearing the path to first-in-human clinical trials scheduled for Q3 2026.
- Most blindness therapies work by stimulating the retina. ReVision’s device bypasses the eye entirely, wiring directly into the brain’s visual cortex to reach patients no existing treatment can help.
- The neuroprosthetics market is valued at $13.43 billion in 2025 and is projected to reach $23.49 billion by 2030, growing at a CAGR of 11.83%, according to Mordor Intelligence.
Every blindness therapy approved today has one requirement: some part of the eye must still work. For the tens of millions of people whose retinas and optic nerves are entirely damaged, there is currently nothing.ReVision Implant is building a device for that patient group and it just raised the money to put it in a human brain for the first time.
The Leuven-based company has closed a €4 million oversubscribed round from private investors, including existing backers and new European medtech operators and business leaders. No single lead investor was named. The raise adds to ReVision’s existing public funding, which includes EU grants totalling nearly €1.5M across the EIC Pathfinder Hyperstim project and the €2.4M EIC Transition FlairVision project, bringing total publicly disclosed funding to over €5.4M. The company is also supported by Plug & Play and imec istart incubators.
What the device does
ReVision Implant was founded in 2020 by Dr Frederik Ceyssens and Prof Peter Janssen of KU Leuven — a microelectronics engineer and a neurophysiologist, respectively — and is headquartered in Leuven, Belgium.
The product is called Occular. A miniature camera mounted on a wireless headset captures visual information, which is processed and transmitted to an implant containing dense arrays of ultra-flexible microelectrodes inserted into the brain’s visual cortex. The cortex interprets the electrical signals as points of light. By targeting the cortex rather than the eye, the system can theoretically restore some form of functional vision to patients blind from any cause — retinal degeneration, optic nerve damage, glaucoma, diabetic retinopathy — regardless of what has been destroyed below the brain.
The technical differentiator is electrode design. ReVision uses thin-film technology to produce ultra-flexible electrodes that the brain tolerates well, and the company argues that thousands of electrode contacts are required to generate a useful image — something earlier, stiffer arrays could not safely provide. Long-term animal studies in rhesus monkeys have demonstrated both biocompatibility and proof of efficacy.
The competitive landscape
The closest direct comparator is Cortigent (formerly part of Second Sight Medical Products), which has been running an NIH-funded feasibility trial of its Orion cortical prosthesis since 2018. Cortigent uses surface electrodes placed on the cortex rather than penetrating into it, limiting resolution. Science Corporation, which raised $230M in a Series C in March 2026 at a reported $1.5 billion valuation, is focused on retinal implants — a different patient population entirely, requiring a partially intact retina. ReVision’s cortex-first approach is the only one targeting patients whom retinal devices cannot help, which is also why it recently received a Breakthrough Device designation from the FDA, accelerating its regulatory pathway.
“This funding round marks an important step as we move from development towards clinical and operational scale-up,” said Ceyssens. “We are investing in our own cleanroom environment to bring important manufacturing steps in-house, while expanding our team and advancing our regulatory compliance and clinical programme over the coming years.”
What comes next
ReVision began building its own cleanroom facilities three months ago — the first step toward controlling its manufacturing quality ahead of clinical trials. Regulatory approval for an acute first-in-human study was filed in Hungary in October 2025; the first phase of trials is now scheduled for Q3 2026. The company has also announced a strategic collaboration with Cochlear, the world leader in cochlear implants, signed in March 2025 — a partnership that signals institutional confidence from within the medtech establishment.
The deeper question this raises is whether the cortical approach to vision restoration will ultimately serve a different, larger patient population than the retinal implant race currently attracting the bulk of capital — and whether a €4M round is sufficient runway to survive long enough to find out.
